Top-News

Lucid Diagnostics Aktie News

Aktie
WKN:  ISIN:  US54948X1090 US-Symbol:  LUCD Branche:  Gesundheitswesen: Ausstattung u. Produkte Land:  USA
1,035 $
-0,025 $
-2,36%
0,8891 € 21:59:53 Uhr
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
48,28%
KGV
-1,04
Index-Zuordnung
-

Lucid Diagnostics News

20.11.25 - PR Newswire
Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree
Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-​Ranking Honoree PR Newswire
13.11.25 - PR Newswire
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum PR Newswire
13.11.25 - PR Newswire
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results PR Newswire
12.11.25 - PR Newswire
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results PR Newswire
29.10.25 - PR Newswire
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025 PR Newswire
15.10.25 - PR Newswire
Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit
Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit PR Newswire
25.09.25 - PR Newswire
Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors
Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors PR Newswire
16.09.25 - PR Newswire
Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs
Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs PR Newswire
11.09.25 - PR Newswire
Lucid Diagnostics Announces Closing of Public Offering of Common Stock
Lucid Diagnostics Announces Closing of Public Offering of Common Stock PR Newswire
10.09.25 - PR Newswire
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock PR Newswire
09.09.25 - PR Newswire
Lucid Diagnostics Announces Proposed Public Offering of Common Stock
Lucid Diagnostics Announces Proposed Public Offering of Common Stock PR Newswire
05.09.25 - PR Newswire
Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025
Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025 PR Newswire
27.08.25 - PR Newswire
Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025
Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025 PR Newswire
26.08.25 - PR Newswire
PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology
PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology PR Newswire
14.08.25 - PR Newswire
PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results
PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results PR Newswire
13.08.25 - PR Newswire
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results PR Newswire
05.08.25 - PR Newswire
Lucid Diagnostics to Participate in Upcoming Investor Conferences
Lucid Diagnostics to Participate in Upcoming Investor Conferences PR Newswire
30.07.25 - PR Newswire
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025 PR Newswire
16.07.25 - PR Newswire
MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test
MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test PR Newswire
18.06.25 - PR Newswire
Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test
Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »